Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 6/20 | 0.45 |
| ▸ | EP300 | Q09472 | 7/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13261399 | 0.95 | TLR8 (0.47) | FGFR1EP300TLR8 | |
| SCHEMBL25628523 | 0.93 | FGFR1 (0.48) | FGFR1EP300TLR8 | |
| SCHEMBL4245808 | 0.93 | FGFR1 (0.48) | FGFR1EP300TLR8 | |
| SCHEMBL13975422 | 0.93 | FGFR1 (0.48) | FGFR1EP300TLR8 | |
| SCHEMBL27723178 | 0.93 | FGFR1 (0.48) | FGFR1EP300TLR8 | |
| SCHEMBL27977634 | 0.93 | FGFR1 (0.48) | FGFR1EP300TLR8 | |
| SCHEMBL2967556 | 0.89 | FGFR1 (0.43) | FGFR1EP300SLC22A6 | |
| SCHEMBL23343373 | 0.89 | FGFR1 (0.44) | FGFR1EP300SLC22A6LMNA | |
| SCHEMBL1532184 | 0.84 | FGFR1 (0.42) | FGFR1EP300SLC22A6LMNA | |
| SCHEMBL20012082 | 0.83 | FGFR1 (0.41) | FGFR1EP300SLC22A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667667-B2 | Steroid derivative FXR agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20230023797-A1 | MAJORITY LOGIC GATE WITH INPUT PARAELECTRIC CAPACITORS | Kepler Computing Inc. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2022132194-A2 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| US-20210322923-A1 | SYSTEM AND PROCESS OF CAPTURING CARBON DIOXIDE FROM FLUE GASES | CARBON CLEAN SOLUTIONS LIMITED (GB) | 2021-10-21 | — | — | US | disclosed |
| US-11141694-B2 | System and process of capturing carbon dioxide from flue gases | CARBON CLEAN SOLUTIONS LIMITED (GB) | 2021-10-12 | — | — | US | disclosed |
| US-20210040140-A1 | Steroid Derivative FXR Agonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10738718-B2 | Bi-fuel engine with increased power | ALSET IP S A R.L. (LU) | 2020-08-11 | — | — | US | disclosed |
| EP-1836285-B1 | INTEGRATED ALKYLATION PROCESS USING IONIC LIQUID CATALYSTS | CHEVRON USA INC (US) | 2019-11-20 | — | — | EP | disclosed |
| WO-2017201325-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| CN-104003945-A | Synthetic method of pyrimidine type chiral surface active agents | UNIV YANGZHOU | 2014-08-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667667-B2 | Steroid derivative FXR agonist | NR1H4, SLC10A1, FXR1 | FGFR1 83/4885EP300 4318/4885TLR8 299/4885 |
| US-20210040140-A1 | Steroid Derivative FXR Agonist | NR1H4, SLC10A1, FXR1 | FGFR1 83/4885EP300 4318/4885TLR8 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.